The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Abstract
1. An antisense oligonucleotide (ASO) is a short strand of deoxyribonucleotide analogue that hybridizes with the complementary mRNA in a sequence-specific manner via Watson-Crick base pairing. Formation of the ASO-mRNA heteroduplex either triggers RNase H activity, leading to mRNA degradation, induces translational arrest by steric hindrance of ribosomal activity, interferes with mRNA maturation by inhibiting splicing or destabilizes pre-mRNA in the nucleus, resulting in downregulation of target protein expression. 2. The ASO is not only a useful experimental tool in protein target identification and validation, but also a highly selective therapeutic strategy for diseases with dysregulated protein expression. 3. In the present review, we discuss various theoretical approaches to rational design of ASO, chemical modifications of ASO, ASO delivery systems and ASO-related toxicology. Finally, we survey ASO drugs in various current clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332 · cited 1×
“Peptide nucleic acid is a synthetic DNA mimic in which the phosphodiester backbone is replaced with a flexible pseudopeptide polymer (N-(2-aminoethyl)glycine) and nucleobases are attached to the backbone via methylene carbonyl linkage.(28,29) Peptide nucleic acid is a non-charged nucleotide analogue that can hybridize”
BackgroundAntisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA
Vester, B., & Wengel, J. (2004) · Biochemistry · doi:10.1021/bi0485732 · Cited by 727
LNA: a versatile tool for therapeutics and genomics
Petersen, M., & Wengel, J. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(02)00038-0 · Cited by 613
Design of antisense oligonucleotides stabilized by locked nucleic acids
Kurreck, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.1911 · Cited by 577
Sfold web server for statistical folding and rational design of nucleic acids
Ding, Y., Chan, C. Y., & Lawrence, C. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh449 · Cited by 518
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417 · cited 11×
“ASO and location of hybridization, resulting in reduced levels of translation of the target transcript.(1) The ASO is not only a useful tool for studies of loss-of-gene function and target validation, but also highly valuable as a novel therapeutic strategy to treat any disease that is linked to dysregulated gene expr…”
BackgroundInfluentialGleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
Phosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
ECKSTEIN, F. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.117 · Cited by 382
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., Tu, D., & Gleave, M. E. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji252 · Cited by 266
Predicting oligonucleotide affinity to nucleic acid targets
MATHEWS, D. H., BURKARD, M. E., FREIER, S. M., WYATT, J. R., & TURNER, D. H. (1999) · RNA · doi:10.1017/s1355838299991148 · Cited by 252
Cellular delivery of peptide nucleic acid (PNA)
Koppelhus, U., & Nielsen, P. E. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00182-5 · Cited by 248
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01327-2 · Cited by 222
McKay, R. A., Miraglia, L. J., Cummins, L. L., Owens, S. R., Sasmor, H., & Dean, N. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1715 · Cited by 220
“Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomes
Fattal, E. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.037 · Cited by 211
Nielsen, P. E. (2004) · Molecular Biotechnology · doi:10.1385/mb:26:3:233 · Cited by 199
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
O'Brien, S. M., Cunningham, C. C., Golenkov, A. K., Turkina, A. G., Novick, S. C., & Rai, K. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4364 · Cited by 194
Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
Ho, S. P., Bao, Y., Lesher, T., Malhotra, R., Ma, L. Y., Fluharty, S. J., & Sakai, R. R. (1998) · Nature Biotechnology · doi:10.1038/nbt0198-59 · Cited by 186
Secondary Structure Prediction of Interacting RNA Molecules
Andronescu, M., Zhang, Z. C., & Condon, A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.10.082 · Cited by 183
Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers
Yoo, H. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.21.4225 · Cited by 181
Effects of RNA secondary structure on cellular antisense activity
Vickers, T. A. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.6.1340 · Cited by 175
The use of cell-penetrating peptides as a tool for gene regulation
Järver, P., & Langel, Ü. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03042-9 · Cited by 174
Ho, S. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.10.1901 · Cited by 164
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
AMANTANA, A., & IVERSEN, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.07.001 · Cited by 163
Toxicology of antisense therapeutics
Jason, T. L. H., Koropatnick, J. D., & Berg, R. W. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.017 · Cited by 161
Ding, Y. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.5.1034 · Cited by 161
Progress in antisense technology: The end of the beginning
Crooke, S. T. (2000) · Methods in Enzymology · doi:10.1016/s0076-6879(00)13003-4 · Cited by 160
van Deventer, S. J. H., Tami, J. A., & Wedel, M. K. (2004) · Gut · doi:10.1136/gut.2003.036160 · Cited by 152
Iversen, P. L., Arora, V., Acker, A., Mason, D. H., & Devi, G. R. (2003) · PubMed · Cited by 145
Bo, X., & Wang, S. (2004) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti211 · Cited by 140
Khan, A., Benboubetra, M., Sayyed, P. Z., Ng, K. W., Fox, S. P., Beck, G., Benter, I. F., & Akhtar, S. (2004) · Journal of drug targeting · doi:10.1080/10611860400003858 · Cited by 134
Altmann, K., Fabbro, D., Dean, N. M., Geiger, T. M., Monia, B. P., Müllert, M., & Nicklin, P. L. (1996) · Biochemical Society Transactions · doi:10.1042/bst0240630 · Cited by 121
Tissue Disposition of 2′‐O‐(2‐methoxy) ethyl Modified Antisense Oligonucleotides in Monkeys
Yu, R. Z., Geary, R. S., Monteith, D., Matson, J. E., Truong, L., Fitchett, J. R., & Levin, A. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10473 · Cited by 114
Devi, G. R., Beer, T. M., Corless, C. L., Arora, V., Weller, D. L., & Iversen, P. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2091 · Cited by 111
Selecting optimal antisense reagents
Sohail, M., & Southern, E. M. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00081-8 · Cited by 104
Badros, A. Z., Goloubeva, O. G., Rapoport, A. P., Ratterree, B., Gahres, N., Meisenberg, B. R., Takebe, N., Heyman, M. R., Zwiebel, J. A., STREICHER, H. Z., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.381 · Cited by 101
Lee, Y., Vassilakos, A., Feng, N., Lam, V., Xie, H., Wang, M., Jin, H., Xiong, K., Liu, C., Wright, J., et al. (2003) · PubMed · Cited by 91
Matveeva, O. V. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.15.2862 · Cited by 90
Rudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., Gokhale, P. C., Steinberg, J., Wanaski, S., Kasid, U. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0642 · Cited by 90
Automatic extraction of mutations from Medline and cross-validation with OMIM
Rebholz‐Schuhmann, D. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh162 · Cited by 87
Innovations in Oligonucleotide Drug Delivery
Lysik, M. A., & Wu‐Pong, S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10399 · Cited by 87
Antisense DNAs as multisite genomic modulators identified by DNA microarray
Cho, Y. S., Kim, M.-K., Cheadle, C., Neary, C. L., Becker, K. G., & Cho‐Chung, Y. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171314398 · Cited by 82
The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses
Paulasova, P., & Pellestor, F. (2004) · Annales de Génétique · doi:10.1016/j.anngen.2004.07.001 · Cited by 82
Thermodynamic criteria for high hit rate antisense oligonucleotide design
Matveeva, O. V. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg710 · Cited by 81
Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann, E., & Vollmer, J. (2003) · PubMed · Cited by 71
Pession, A., & Tonelli, R. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009054064606 · Cited by 71
Intracellular Uptake and Inhibition of Gene Expression by PNAs and PNA−Peptide Conjugates
Kaihatsu, K., Huffman, K. E., & Corey, D. R. (2004) · Biochemistry · doi:10.1021/bi048519l · Cited by 70
Modulation of CpG Oligodeoxynucleotide-Mediated Immune Stimulation by Locked Nucleic Acid (LNA)
Vollmer, J., Stenvang, J., Uhlmann, E., Schetter, C., Jurk, M., Wader, T., Wüllner, M., & Krieg, A. Μ. (2004) · Oligonucleotides · doi:10.1089/154545704322988021 · Cited by 59
Desai, A. A., Schilsky, R. L., Young, A. H., Janisch, L. A., Stadler, W. M., Vogelzang, N. J., Cadden, S., Wright, J. R., & Ratain, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi178 · Cited by 59
Toxicity of Antisense Oligonucleotides
Levin, A. A., Henry, S. P., Monteith, D., & Templin, M. V. (2001) · CRC Press eBooks · doi:10.1201/9781420002546.ch9 · Cited by 48
Computational antisense oligo prediction with a neural network model
Chalk, A. M., & Sonnhammer, E. L. L. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.12.1567 · Cited by 42
Concepts to automate the theoretical design of effective antisense oligonucleotides
Far, R. K., Nedbal, W., & Sczakiel, G. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.11.1058 · Cited by 40
Simões‐Wüst, A. P., Hopkins-Donaldson, S., Sigrist, B., Belyanskaya, L. L., Stahel, R. A., & Zangemeister‐Wittke, U. (2004) · Oligonucleotides · doi:10.1089/oli.2004.14.199 · Cited by 36
Biroccio, A., D’Angelo, C., Jansen, B., Gleave, M. E., & Zupi, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20295 · Cited by 34
Yang, S.-P., Song, S., Tang, Z.-M., & Song, H. (2003) · PubMed · Cited by 18
FEI, J., & Zhang, Y. (2005) · Cell Biology International · doi:10.1016/j.cellbi.2005.04.009 · Cited by 4
Cited by
Di Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
Ki67 is a promising molecular target in the diagnosis of cancer (Review)
LI, L. T., JIANG, G., CHEN, Q., & ZHENG, J. N. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2914 · Cited by 859
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
STAT3 inhibition of gluconeogenesis is downregulated by SirT1
Nie, Y., Erion, D. M., Yuan, Z., Dietrich, M., Shulman, G. I., Horvath, T. L., & Gao, Q. (2009) · Nature Cell Biology · doi:10.1038/ncb1857 · Cited by 334
Metadata
- Authors
- Chan, J. H., Lim, S., & Wong, W. F.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2006-05
- Volume
- 33
- Issue
- 5-6
- Pages
- 533-540
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2014921813
- Cited by
- 430
- References
- 59
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.